Third quarter results
Xillix Technologies Corp XLX
Shares issued 28,400,000 Oct 15 close $0.85
Fri 16 Oct 98 News Release
Mr. Pierre Leduc reports
For the third quarter ended Sept. 30, 1998 total revenues have increased
compared to the same period last year as a result of contract revenue and
sales of the Xillix LIFE-Lung Fluorescence Endoscopy System.
Highlights for the third quarter include an improved loss per share and
increased control of expenses; the U.S. Patent Office issued Xillix a
notice of allowance of a new patent for an "Endoscope Having an Integrated
CCD (Charged Coupled Device) Sensor"; several papers were presented on the
Xillix LIFE-Lung Fluorescence Endoscopy System at international congresses;
and a paper was presented at an international conference on the Xillix
LIFE-GI Fluoresence Endoscopy System based on the clinical tests taking
place in Amsterdam.
STATEMENT OF LOSS
Three months ended Sept. 30
1998 1997
REVENUE
Product sales $946,384 $1,009,143
Contract revenue 412,060 -
Interest income 88,617 44,396
---------- ---------
1,447,061 1,053,539
---------- ---------
EXPENSES
Cost of sales 747,250 943,798
Research and
development 814,138 825,269
Marketing, sales
and support 221,846 241,522
General and
administrative 359,715 392,367
Depreciation and
amortization 229,625 247,018
Other (30,575) (6,804)
---------- ---------
2,341,999 2,643,170
---------- ---------
Loss from
operations 894,938 1,589,631
Gain on divesti-
ture of 1/3
interest in af-
filiated company,
net - -
---------- ---------
Net loss $894,938 $1,589,631
========== ==========
Loss per share 3 cents 6 cents
STATEMENT OF LOSS
Nine months ended Sept. 30
1998 1997
REVENUE
Product sales $2,640,485 $2,046,647
Contract revenue 729,784 1,205,455
Interest income 193,387 116,156
---------- ---------
3,563,656 3,368,258
---------- ---------
EXPENSES
Cost of sales 2,176,185 1,904,423
Research and
development 2,468,775 2,396,649
Marketing, sales
and support 634,547 765,481
General and
administrative 1,232,420 1,348,603
Depreciation and
amortization 702,609 719,975
Other (102,858) (14,512)
---------- ---------
7,111,678 7,120,619
---------- ---------
Loss from
operations 3,548,022 3,752,361
Gain on divesti-
ture of 1/3
interest in af-
filiated company,
net 636,420 -
---------- ---------
Net loss $2,911,602 $3,752,361
========== ==========
Loss per share 10 cents 15 cents |
